Mindsera vs Skrive

Mindsera is an AI-powered journal that analyzes thoughts, detects emotions and surfaces patterns over time. Users can write, speak or photograph a physical journal page to extract its text. Entry analysis breaks down themes, emotions and takeaways, and can generate artwork; a conversational companion draws on earlier entries to ask questions, while Minds highlight parts of writing and comment on them. The service offers more than 52 journaling templates based on mental models and frameworks. Mindsera is available on the web, iOS and Android, with an Apple Watch voice-journaling app. Its mobile app can connect journaling and mood data with Apple Health. The company says journal writing is encrypted at rest and in transit, exportable in Markdown or PDF, and not used to train or improve AI models. It does not use end-to-end encryption because the AI features require processing by its systems and relevant providers. Mindsera says its AI is optimized for English and quality in other languages is not guaranteed. A free plan and trial are listed; paid plans start at $10.75/mo when billed annually.

Skrive is a daily journal built around one plain-text entry per day. Users can browse entries by date and search the full text of their journal history. The free app does not limit how much users can write, and entries are saved locally first, so writing and reading can continue offline or when the cloud service is unavailable. Skrive is available for macOS, iOS, and Android, and entries can be exported as JSON or plain text. Before transmission, entries are encrypted on the device with AES-256 using a key controlled by the user. The maker says encrypted backups are stored on servers in the EU. Skrive Pro adds encrypted cloud backup and sync across devices; it is listed at $3.99 a month. The encryption passphrase cannot be recovered if lost, and entries may become inaccessible after signing out, changing devices, or reinstalling the app. The maker is based in Oslo, Norway. The product has a free plan and a 14-day trial.